Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized crossover trial of QMF149 vs budesonide in children with asthma
2022-501899-26-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of atectura breezhaler in asthma (2 arms), sponsored by Novartis. Primary endpoint: Change in FEV1 at Week 12. Planned start May 2023; status: authorised.
02
Drugs
atectura breezhaler
03
Conditions
asthma
Beyond the preview
Go deeper on 2022-501899-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501899-26-00.